{"id":"bentracimab-pb2452-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL4594327","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bentracimab is a selective heparin-binding monoclonal antibody designed to rapidly neutralize unfractionated heparin in patients who require urgent reversal of anticoagulation. It binds directly to UFH molecules, preventing their interaction with antithrombin and restoring normal coagulation. This mechanism allows for rapid hemostasis in bleeding emergencies or before urgent procedures in heparinized patients.","oneSentence":"Bentracimab is a monoclonal antibody that binds to and neutralizes unfractionated heparin (UFH), rapidly reversing its anticoagulant effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:56.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of unfractionated heparin anticoagulation in patients with acute bleeding or requiring urgent procedures"}]},"trialDetails":[{"nctId":"NCT04286438","phase":"PHASE3","title":"Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2020-07-15","conditions":"Hemorrhage, Urgent Surgery, Invasive Procedure","enrollment":226},{"nctId":"NCT04122170","phase":"PHASE2","title":"Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2019-09-24","conditions":"Healthy","enrollment":207},{"nctId":"NCT05162131","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers","status":"TERMINATED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2021-12-25","conditions":"Healthy","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bentracimab (PB2452) Infusion","genericName":"Bentracimab (PB2452) Infusion","companyName":"SFJ Pharmaceuticals, Inc.","companyId":"sfj-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bentracimab is a monoclonal antibody that binds to and neutralizes unfractionated heparin (UFH), rapidly reversing its anticoagulant effects. Used for Reversal of unfractionated heparin anticoagulation in patients with acute bleeding or requiring urgent procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}